Format

Send to

Choose Destination
J Clin Gastroenterol. 2013 Oct;47(9):814. doi: 10.1097/MCG.0b013e3182951b6c.

Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?

Author information

1
*Preclinical Development †Clinical Development, R&D Alfa Wassermann SpA, Bologna, Italy.
PMID:
23751850
DOI:
10.1097/MCG.0b013e3182951b6c
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center